Background: Cardiovascular disease in patients with breast cancer is of growing concern.
The longitudinal effects of commonly used therapies, including doxorubicin and …

Objectives: This study determined the effects of doxorubicin and/or trastuzumab on diastolic
function and the relationship between diastolic function and systolic dysfunction …

Objectives: This study sought to determine the relationships between echocardiography-
derived measures of myocardial mechanics and cancer therapeutics–related cardiac …

As breast cancer survival increases, cardiotoxicity associated with chemotherapeutic
regimens such as anthracyclines and trastuzumab becomes a more significant issue …

Background Trastuzumab, a HER2 monoclonal antibody, has transformed the prognosis of
patients with the aggressive HER2-positive breast cancer type. Trastuzumab augments the …

Importance Diagnosis of cancer therapy–related cardiac dysfunction (CTRCD) remains a
challenge. Cardiovascular magnetic resonance (CMR) provides accurate measurement of …

Background—Because cancer patients survive longer, the impact of cardiotoxicity
associated with the use of cancer treatments escalates. The present study investigates …

Abstract Background MANTICORE 101-Breast (Multidisciplinary Approach to Novel
Therapies in Cardiology Oncology Research) is a randomized trial to determine if …

Background Trastuzumab improves dramatically the prognosis of HER2‐positive breast
cancer patients, but it may lead to cardiotoxicity with left ventricular (LV) systolic dysfunction …

Background Trastuzumab is life‐extending therapy for breast cancer patients
overexpressing the human epidermal growth factor receptor 2 (HER 2+), but has known …